Phase I/II Study of Subcutaneously Administered Veltuzumab (hA20) in Patients with CD20+ Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Study Status

Open to Enrollment

Study Description

Note: this study is currently open only to people with Chronic Lymphocytic Leukemia (CLL). Enrollment is now closed to non-Hodgkin lymphoma patients.

This is the first study to be done with subcutaneous injections of veltuzumab (hA20). The purpose of the study is to evaluate the use of the study drug in people with CD20+ B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. The study drug will be tested to see if it can safely be administered under the skin and if it is well tolerated. The study drug will also be tested to see if it is effective in treating lymphoma and leukemia. Veltuzumab (hA20) is an experimental drug.

Study participation is expected to last for approximately 2 years. Study participants will receive subcutaneous injections of the study drug twice a week for a total of 16 injections over 8 weeks. Participants will then return at intervals up to 12 weeks for blood samples and evaluations to see if their disease responded.

Disease Status and/or Stage

Untreated or Relapsed Chronic Lymphocytic Leukemia

Sponsor

Immunomedics

Key Eligibility

  • Men and women age 18 and older
  • Diagnosed with CLL
  • Previously untreated or relapsed
  • Detailed eligibility reviewed when you contact the study team

Principal Investigator

Rebecca Elstrom, MD

Contact

Healthy Volunteers

healthy_volunteers.jpg

As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
roh2026@med.cornell.edu

Top of page